2006
DOI: 10.1001/archderm.142.7.927
|View full text |Cite
|
Sign up to set email alerts
|

A Randomized, Placebo-Controlled, Double-blind Trial Comparing Narrowband UV-B Plus 0.1% Tacrolimus Ointment With Narrowband UV-B Plus Placebo in the Treatment of Generalized Vitiligo

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
39
1

Year Published

2009
2009
2018
2018

Publication Types

Select...
5
2
2

Relationship

0
9

Authors

Journals

citations
Cited by 56 publications
(40 citation statements)
references
References 5 publications
0
39
1
Order By: Relevance
“…30 Topical CIs work well as adjunctive therapy. Although a small randomized, double-blinded placebo controlled trial found no benefit for adding topical tacrolimus to NBUVB phototherapy, 31 others have shown repigmentation rates of more than 50% in 42% of lesions in patients with chronic stable refractory vitiligo 32 and that combination therapy can provide additional benefit for facial lesions. 33 Studies combining topical tacrolimus with the 308-nm excimer laser have shown even more promising results.…”
Section: Efficacymentioning
confidence: 98%
See 1 more Smart Citation
“…30 Topical CIs work well as adjunctive therapy. Although a small randomized, double-blinded placebo controlled trial found no benefit for adding topical tacrolimus to NBUVB phototherapy, 31 others have shown repigmentation rates of more than 50% in 42% of lesions in patients with chronic stable refractory vitiligo 32 and that combination therapy can provide additional benefit for facial lesions. 33 Studies combining topical tacrolimus with the 308-nm excimer laser have shown even more promising results.…”
Section: Efficacymentioning
confidence: 98%
“…Common side effects include erythema, pruritis, burning, and irritation 6,14,22,24,31 ; hyperpigmentation and acne are less frequent. [35][36][37] As a precautionary measure, the product label revisions approved by the US Food and Drug Administration (FDA) for topical CIs in January 2006 were based on a theoretical risk arising from the systemic use of CIs in transplant recipients and animal studies.…”
Section: Safetymentioning
confidence: 99%
“…7 Based on the report by Westerhof and NieuweboerKrobotova, 6 the guidelines for the treatment of vitiligo 8 that were published in 1999eand have not been revised yeteproposed NB-UVB as first-choice therapy for generalized vitiligo in adults and as alternative therapy, after class-III corticosteroids, for vitiligo in children. In the following years, several studies assessed the efficacy of NB-UVB alone 3,[9][10][11][12][13][14][15][16][17][18] or in combination with other agents [19][20][21][22][23][24][25][26][27][28][29][30][31] in the treatment of vitiligo with variable results. A number of studies [32][33][34][35] have also compared the efficacy of NB-UVB with that of PUVA in patients with vitiligo and have reported comparable or slightly better efficacy for NB-UVB.…”
mentioning
confidence: 99%
“…Treatment options that have been used with NB-UVB in vitiligo till date include topical tacrolimus, 14,15 pimecrolimus, 16 Vitamin D analogues 17,18 and even topical pseudocatalase 19 . While some studies have shown a synergistic effect with these combinations, others have found the efficacy of the combinations to be similar to NB-UVB alone.…”
Section: Nb-uvbmentioning
confidence: 99%